SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal administration to treat vulvovaginal atrophy (VVA) in women without the…Read More
Dar Bioscience Inc Dar Bioscience Announces Publication of Phase 12 Pharmacokinetic Safety and Pharmacodynamic Data for DAREVVA1 a Potential New HormoneFree Treatment for Vulvovaginal Atrophy in Climacteric the Journal of the International M
